Century Therapeutics (IPSC) Net Income towards Common Stockholders (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$21.7 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$21.7 million, down 128.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.2 million (down 365.81% YoY), and the FY2025 annual result was $39000.0, up 100.03% from the prior year.
• Net Income towards Common Stockholders declined to -$21.7 million in Q1 2026 per IPSC's latest filing, from -$9.5 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $76.6 million in Q1 2025 and troughed at -$39.4 million in Q4 2023.
• A 5-year average of -$24.4 million and a median of -$31.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders soared 372.82% in 2025, then tumbled 128.3% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$31.7 million in 2022, then retreated by 24.38% to -$39.4 million in 2023, then climbed by 10.65% to -$35.2 million in 2024, then surged by 72.88% to -$9.5 million in 2025, then sank by 126.93% to -$21.7 million in 2026.
• Business Quant data shows IPSC's Net Income towards Common Stockholders at -$21.7 million in Q1 2026, -$9.5 million in Q4 2025, and -$34.4 million in Q3 2025.